Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 6/20 | 0.34 |
| ▸ | CNR1 | P21554 | 4/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944817 | 0.92 | RAB9A (0.40) | PTGESRAB9ANPC1TAS1R3TAS1R1 | |
| SCHEMBL9944902 | 0.90 | RAB9A (0.39) | PTGESRAB9ANPC1TAS1R3TAS1R1 | |
| SCHEMBL9898474 | 0.90 | PTGES (0.48) | PTGESDPP4DPP7 | |
| SCHEMBL9898477 | 0.90 | PTGES (0.48) | PTGESDPP4DPP7 | |
| SCHEMBL9944894 | 0.88 | PTGES (0.38) | PTGESRAB9ANPC1TAS1R3TAS1R1 | |
| SCHEMBL9944950 | 0.88 | RAB9A (0.40) | RAB9ANPC1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL9944886 | 0.86 | RAB9A (0.39) | PTGESRAB9ANPC1TAS1R3TAS1R1 | |
| SCHEMBL9944746 | 0.85 | POLB (0.39) | PTGESRAB9ANPC1TAS1R3TAS1R1 | |
| SCHEMBL9944909 | 0.85 | RAB9A (0.40) | PTGESRAB9ANPC1TAS1R3TAS1R1 | |
| SCHEMBL9944826 | 0.85 | RAB9A (0.41) | PTGESRAB9ANPC1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | PTGES 3/4885RAB9A 1033/4885NPC1 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.